Congenital Adrenal Hyperplasia Clinical Trials 2024

Congenital Adrenal Hyperplasia Clinical Trials 2024

Congenital Adrenal Hyperplasia research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in congenital adrenal hyperplasia clinical trials today.

Congenital Adrenal Hyperplasia Clinical Trials

Here are the 6 most popular medical studies for congenital adrenal hyperplasia

Popular filter options for congenital adrenal hyperplasia trials

Enlarged Prostate Clinical Trials

View 23 Enlarged Prostate medical studies.

CAH Clinical Trials

View 13 CAH medical studies.

Phase 3 Congenital Adrenal Hyperplasia Clinical Trials

View 71 phase 3 congenital adrenal hyperplasia medical studies.

Congenital Adrenal Hyperplasia Clinical Trials With No Placebo

View 71 congenital adrenal hyperplasia medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to congenital adrenal hyperplasia

What are the top hospitals conducting congenital adrenal hyperplasia research?

In the realm of clinical trials for congenital adrenal hyperplasia, cutting-edge research is being conducted at several esteemed hospitals across the United States. Located in Bethesda, Maryland, the National Institutes of Health Clinical Center leads the pack with four active trials dedicated to this rare condition. This renowned institution has been at the forefront of congenital adrenal hyperplasia research since recording its first trial back in 1995. Meanwhile, at the University of Wisconsin Hospital and Clinics in Madison, three ongoing trials are currently underway to address this complex disorder. Although they have yet to conduct any prior studies on congenital adrenal hyperplasia, their commitment to breaking new ground is evident.

Similarly committed institutions include The University of North carolina at Chapel Hill and The University of Minnesota/Masonic Cancer Center. Both facilities have two active clinical trials exploring viable treatments for congenital adrenal hyperplasia but have not previously conducted any studies on this specific condition until now.

Even further afield lies Queen's Medical Center located amidst sunny Honolulu where researchers are also dedicating themselves to making strides against this challenging disorder through two current congenital adrenal hyperplasia clinical trials; although Queen's Medical Centre hasn’t explored such experiments before recently.

These top hospitals represent beacons of hope for individuals affected by congenital adrenal hyperplasia as well as testaments to medical advancement on a national scale. Their unwavering dedication toward understanding and treating this rare condition brings us ever closer to improving the lives of those touched by it while reinforcing that progress knows no geographical bounds

Which are the best cities for congenital adrenal hyperplasia clinical trials?

When it comes to congenital adrenal hyperplasia clinical trials, several cities emerge as leading hubs for research and development. Houston, Texas takes the top spot with 14 active trials exploring treatments like Levonorgestrel-Releasing Intrauterine System, Ruxolitinib, Prolieve, and more. New york City closely follows with 12 ongoing studies focused on interventions such as Crinecerfont and Decision Aid. Honolulu, Hawaii also shows promise with 11 active trials investigating options like Decision Aid and Levonorgestrel-Releasing Intrauterine System. Indianapolis, Indiana and Los Angeles, California each have 10 active trials studying various treatments including Tildacerfont and Abiraterone acetate. These cities offer individuals affected by congenital adrenal hyperplasia access to cutting-edge clinical trials that pave the way for advancements in care and potential breakthroughs in treatment options.

Which are the top treatments for congenital adrenal hyperplasia being explored in clinical trials?

Clinical trials are illuminating promising treatments for congenital adrenal hyperplasia, offering hope to those affected by this condition. One standout contender is Chronocort, currently being explored in two active trials for congenital adrenal hyperplasia. Since its debut in 2007, it has been part of five clinical trials dedicated to addressing this disorder. Another potential breakthrough comes from Crinecerfont, a newcomer that has already caught the attention of researchers with two ongoing trials and two all-time studies focused on treating congenital adrenal hyperplasia since its introduction in 2020. As these investigations progress, new avenues may open up for individuals living with this challenging condition.

What are the most recent clinical trials for congenital adrenal hyperplasia?

New developments in clinical trials offer hope for individuals with congenital adrenal hyperplasia. One such trial focuses on sequential dosing, aiming to optimize treatment strategies for this condition. Another study investigates the potential benefits of APG-157 therapy, which could provide a valuable therapeutic option. Additionally, researchers are exploring the use of allogeneic umbilical cord tissue-derived mesenchymal stromal cells as a potential treatment approach. These groundbreaking studies demonstrate ongoing efforts to improve the management and outcomes associated with congenital adrenal hyperplasia.

What congenital adrenal hyperplasia clinical trials were recently completed?

A recent clinical trial investigating treatments for congenital adrenal hyperplasia has yielded promising results. In January 2019, the University of Minnesota successfully completed a trial evaluating the efficacy of subcutaneous hydrocortisone therapy. This important milestone brings us closer to improved management options for individuals with congenital adrenal hyperplasia, highlighting the dedication and progress made by researchers in this field.